Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application?
Haller
G W
GW
Department of Surgery, Virchow Clinic, Humboldt University, Berlin, Germany.
Winkler
M
M
Bechstein
W O
WO
Oldhafer
K J
KJ
Ringe
B
B
Maibücher
A
A
Färber
L
L
Pichlmayr
R
R
Neuhaus
P
P
D000284:Administration, Oral; D000328:Adult; D016572:Cyclosporine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D004304:Dosage Forms; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D007275:Injections, Intravenous; D007408:Intestinal Absorption; D016031:Liver Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D013997:Time Factors
D004304:Dosage Forms; D007166:Immunosuppressive Agents; D016572:Cyclosporine